Evidence map›Paper›PMID 11861825›Full record

ArticleJournal of virology2002

CD4 independence of simian immunodeficiency virus Envs is associated with macrophage tropism, neutralization sensitivity, and attenuated pathogenicity.

Bridget A Puffer, Stefan Pöhlmann, Aimee L Edinger, Dan Carlin, Melissa D Sanchez, Julie Reitter, Debbie D Watry, Howard S Fox, Ronald C Desrosiers, Robert W Doms

Open access · greenAbstract read
In one paragraph

Article in Journal of virology, 2002. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 75 papers.

0numbers the graph read from it
0cells of the map it votes in
75citing papers in PubMed
4.2field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

75 citing papers in PubMed, 122 citations in OpenAlex.

  1. Article
  2. HIV envelope tail truncation confers resistance to SERINC5 restriction.Proceedings of the National Academy of Sciences of the United States of America · 2021
    Article
  3. Review
  4. Journal of virology · 2019
    Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Enhanced antagonism of BST-2 by a neurovirulent SIV envelope.The Journal of clinical investigation · 2016
    Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article

15 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 3 institutions in 1 country.

Bridget A PufferDepartment of Microbiology, University of Pennsylvania, Philadelphia, Pennsylvania 19104, USA.
Stefan Pöhlmann
Aimee L Edinger
Dan Carlin
Melissa D Sanchez
Julie Reitter
Debbie D Watry
Howard S Fox
Ronald C Desrosiers
Robert W Doms
Harvard University · USScripps Research Institute · USUniversity of Pennsylvania · US

Funding

ZETA CHAIN OF T CELL RECEPTOR INTERACTS W/ NEF OF SIV &HIV2P51RR000168 · NCRR · HARVARD UNIVERSITY (MEDICAL SCHOOL) · PI WESTMORELAND, SUSAN V. · 1985 to 2011
$139.3M
Therapeutics Core (Page 286)P30MH062261 · NIMH · UNIVERSITY OF NEBRASKA MEDICAL CENTER · PI GENDELMAN, HOWARD E · 2000 to 2021
$37.7M
PROTECTIVE EFFICACY OF LIVE ATTENUATED SIV VACCINESP01AI035365 · NIAID · HARVARD UNIVERSITY (MEDICAL SCHOOL) · PI DESROSIERS, RONALD C · 1998 to 2004
$8.5M
NEUROIMMUNE FACTORS IN SIV INDUCED CNS DYSFUNCTIONR01MH061224 · NIMH · SCRIPPS RESEARCH INSTITUTE · PI FOX, HOWARD S. · 1999 to 2003
$1.3M
MOUSE MODELS OF CANCER, BONE DISEASE, AND LACTATIONK26RR000168 · NCRR · OHIO STATE UNIVERSITY · PI ROSOL, THOMAS J · 2000 to 2004
$547k
MINORITY PREDOCTORAL FELLOWSHIP PROGRAMF31RR005074 · NCRR · UNIVERSITY OF PENNSYLVANIA · PI SANCHEZ, MELISSA · 2000 to 2004
$169k
DEVELOPMENT OF NOVEL SIV VACCINES TARGETING VIRUS ENTRYF32AI010577 · NIAID · UNIVERSITY OF PENNSYLVANIA · PI PUFFER, BRIDGET A · 2000 to 2002
$119k
SAFETY AND EFFICACY OF LIVE ATTENUATED SIV DELETION MUTANTSU01AI035365 · NIAID · HARVARD UNIVERSITY (MEDICAL SCHOOL) · 1994 to 1998
–
NCRR NIH HHS F31 RR005074NCRR NIH HHS F31 RR05074NCRR NIH HHS K26 RR000168NCRR NIH HHS P51 RR000168NCRR NIH HHS RR00168NIAID NIH HHS AI 25338NIAID NIH HHS AI 35365NIAID NIH HHS F32 AI010577NIAID NIH HHS F32 AI 10577NIAID NIH HHS P01 AI035365NIAID NIH HHS U01 AI035365NIMH NIH HHS MH61224NIMH NIH HHS MH62261NIMH NIH HHS P30 MH062261PHS HHS R01 35383PHS HHS R01 40880
6 · The paper itself

Abstract

To investigate the basis for envelope (Env) determinants influencing simian immunodeficiency virus (SIV) tropism, we studied a number of Envs that are closely related to that of SIVmac239, a pathogenic, T-tropic virus that is neutralization resistant. The Envs from macrophage-tropic (M-tropic) virus strains SIVmac316, 1A11, 17E-Fr, and 1100 facilitated infection of CCR5-positive, CD4-negative cells. In contrast, the SIVmac239 Env was strictly dependent upon the presence of CD4 for membrane fusion. We also found that the Envs from M-tropic virus strains, which are less pathogenic in vivo, were very sensitive to antibody-mediated neutralization. Antibodies to the V3-loop, as well as antibodies that block SIV gp120 binding to CCR5, efficiently neutralized CD4-independent, M-tropic Envs but not the 239 Env. However, triggering the 239 Env with soluble CD4, presumably resulting in exposure of the CCR5 binding site, made it as neutralization sensitive as the M-tropic Envs. In addition, mutations of N-linked glycosylation sites in the V1/V2 region, previously shown to enhance antigenicity and immunogenicity, made the 239 Env partially CD4 independent. These findings indicate that Env-based determinants of M tropism of these strains are generally associated with decreased dependence on CD4 for entry into cells. Furthermore, CD4 independence and M tropism are also associated with neutralization sensitivity and reduced pathogenicity, suggesting that the humoral immune response may exert strong selective pressure against CD4-independent M-tropic SIVmac strains. Finally, genetic modification of viral Envs to enhance CD4 independence may also result in improved humoral immune responses.

Indexed as

AnimalsAntibodies, ViralCD4 AntigensCell LineGene Products, envHumansMacaca mulattaMacrophagesNeutralization TestsReceptors, CCR5Simian Acquired Immunodeficiency SyndromeSimian Immunodeficiency VirusVirulenceAntibodies, ViralCD4 AntigensGene Products, envReceptors, CCR5

Identifiers

PMID11861825
PMCPMC135960
OpenAlexW2107298174

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.